C4 Therapeutics (CCCC) TD Cowen 46th Annual Health Care Conference summary

Strategic vision and pipeline overview

• Focus on targeted protein degradation with a validated clinical oncology portfolio and a sustainable pipeline vision through 2028, including cemsidomide as a lead asset.

• Discovery strategy expanded to inflammation, neuroinflammation, and neurodegeneration, targeting undruggable proteins in validated pathways.

• Financial runway secured through 2028, supporting key milestones and multiple INDs from the discovery portfolio.

• Active collaborations with Roche, Merck KGaA, and Biogen, with productive progress in autoimmune and oncology programs.

Clinical development and trial updates

• MOMENTUM phase II study for cemsidomide has begun enrollment, with global site expansion and a 12-month enrollment target.

• Phase Ib combination study with elranatamab to start next quarter, aiming to optimize dosing and inform phase III design.

• Decision on EGFR L858R degrader (CFT8919) program expected based on ongoing phase I data in China.

• Early read on MOMENTUM response rates and combination data expected in the second half of the year; registrational dataset anticipated in 2028.

Cemsidomide profile and differentiation

• Cemsidomide demonstrates a best-in-class efficacy and safety profile among IKZF1/3 degraders, with robust activity in late-line, heavily pretreated myeloma patients.

• No dose discontinuations due to toxicity and low rates of dose reductions compared to competitors, supporting sustained dosing.

• 14-day on/14-day off dosing cycle facilitates combination with other therapies and patient tolerability.

• Differentiated from CELMoDs by a more favorable balance of efficacy and safety, and a broader therapeutic window.